AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26281907
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg/day for 21 days
Trial: 26282537
Drug: Clinical treatment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical treatment offered to all infected participants.
Trial: 26282634
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of methotrexate and cytarabine followed by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT). Treatment included eight doses of rituximab and four doses of intrathecal liposomal cytarabine.
Trial: 26283670
Drug: Azithromycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1.5 g for 5 days)
Trial: 26283670
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g single oral dose)
Trial: 26284932
Drug: Methylphenidate (osmotic-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (osmotic-release oral system)
Trial: 26285768
Drug: Tamoxifen (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (120 mg PO twice daily) and bortezomib (1.3 mg/m2 IV on specified days) per 6-week cycles
Trial: 26288246
Drug: Open-label venlafaxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks
Trial: 26288277
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) via single colonoscopic administration
Trial: 26291296
Drug: Anti-TNF-α agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α agents in patients with AS
Trial: 26292221
Drug: Pomalidomide 2
RxNorm normalized name: pomalidomide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 2 mg (Cohort 1)
Trial: 26292221
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg (Cohort 2)
Trial: 26293470
Drug: Automated electronic
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated electronic reminders for earlier switching from i.v. to p.o. antibiotics
Trial: 26293568
Drug: SmartCare services
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SmartCare services with remote monitoring and health care services in addition to existing treatment.
Trial: 26293568
Drug: Existing outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing outpatient treatments (control group).
Trial: 26293568
Drug: Existing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing treatment (control group).
Trial: 26296092
Drug: CC-486 (300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (300mg once-daily for 14 or 21 days per 28-day cycle)
Trial: 26296092
Drug: CC-486 (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (200mg twice-daily for 14 or 21 days per 28-day cycle)
Trial: 26296092
Drug: CC-486 (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (200mg twice-daily for 21 days per 28-day cycle)
Trial: 26296092
Drug: CC-486 (300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (300mg once-daily for 21 days per 28-day cycle)
Trial: 26296092
Drug: CC-486 (extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (extended dosing)
Trial: 26296295
Drug: Afatinib 40mg
RxNorm normalized name: AFATINIB 40MG TAB
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 40mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Trial: 26296295
Drug: Afatinib 50mg
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 50mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Trial: 26296295
Drug: Afatinib and
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib and paclitaxel combination
Trial: 26296371
Drug: Irreversible electroporation
RxNorm normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irreversible electroporation (IRE) treatment of the prostate
Trial: 26296952
Drug: RRx-001 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 (10 mg/m(2), 16·7 mg/m(2), 24·6 mg/m(2), 33 mg/m(2), 55 mg/m(2), 83 mg/m(2))
Trial: 26296952
Drug: RRx-001 (16·7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 (16·7 mg/m(2))
Trial: 26299414
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with prescribed medications or other therapies
Trial: 26300782
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day XOS for 8 weeks
Trial: 26300919
Drug: Amoxicillin/Clavulanic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/Clavulanic Acid (875 mg/125 mg BID, n = 235)
Trial: 26300919
Drug: Clindamycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (150 mg QID, n = 237)
Trial: 26300919
Drug: Amoxicillin/Clavulanic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/Clavulanic Acid
Trial: 26300919
Drug: Amoxicillin/Clavulanic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/Clavulanic Acid and Clindamycin
Trial: 26300986
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg daily, n=87)
Trial: 26301100
Drug: Edratide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edratide 0.5 mg
Trial: 26301100
Drug: Edratide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edratide 1.0 mg
Trial: 26301100
Drug: Edratide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edratide 2.5 mg
Trial: 26301100
Drug: Edratide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edratide (all doses)
Trial: 26304481
Drug: Dual intramuscular
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual intramuscular and intra-arterial injection of bone marrow mononuclear cells harvested from the iliac crest
Trial: 26304866
Drug: Dabigatran treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran treatment initiated within 24 hours of minor stroke, continued for 30 days.
Trial: 26304872
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 10 mg/kg once per week (cohort A)
Trial: 26304872
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 15 mg/kg once per week (cohort B)
Trial: 26305021
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of levobupivacaine 0.5 % (2 ml/h for 48 hours)
Trial: 26305021
Drug: Saline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2 ml/h for 48 hours)
Trial: 26306290
Drug: Desmopressin (dDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (dDAVP) administered by intravenous infusion in saline, 30-60 min before and 24 h after surgical resection.
Trial: 26308285
Drug: Tumor-infiltrating lymphocytes
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-infiltrating lymphocytes (TILs) therapy
Trial: 26308942
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring of gemcitabine
Trial: 26310540
Drug: Latent iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latent iron deficiency (serum ferritin ≤75 ng/mL)
Trial: 26310540
Drug: Normal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal iron status (serum ferritin >75 ng/mL)
Trial: 26310596
Drug: Control for
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control for alternative sex-linked explanations (i.e., depression and drug use)
Trial: 26310837
Drug: CC rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CC rate 100-120/min and CC depth ≥ 60 mm (without mattress deflection correction)
Trial: 26310837
Drug: CC depth
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC depth
Trial: 26310837
Drug: Deeper CC
RxNorm normalized name: Titanium Dioxide 0.38 g in 4.25 g TOPICAL POWDER [Purminerals 4 in 1 Makeup SPF 15 Deeper]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deeper CC
Trial: 26310975
Drug: RG7256 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7256 (200 mg QD to 2400 mg BID)
Trial: 26310975
Drug: RG7256 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7256 (high dose levels >1200 mg BID)
Trial: 26312070
Drug: Vildagliptin added-on
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin added-on to metformin
Trial: 26312070
Drug: Glibenclamide added-on
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide added-on to metformin
Trial: 26312852
Drug: Valaciclovir (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir (8 g daily) for 6 months
Trial: 26312852
Drug: Valaciclovir (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir (8 g daily)
Trial: 26313445
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) 60 mg once daily plus PEG-IFN 180 µg weekly and RBV 1,000-1,200 mg/day (weight-based) twice daily
Trial: 26314624
Drug: 17D-204 yellow
RxNorm normalized name: Flavivirus yellow fever virus 17D-204 whole
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17D-204 yellow fever vaccine (Stamaril, Sanofi-Pasteur, Lyon, France), 8 vials of lyophilized vaccine, viral quantification, cloning and sequencing of C/prM/E region.
Trial: 26314729
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose challenge
Trial: 26314729
Drug: Oral lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipid challenge
Trial: 26314740
Drug: Standardized measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized measurement of CRP levels with enhanced CT-scan if CRP exceeds 140 mg/L on postoperative day 3, 4, or 5.
Trial: 26314822
Drug: Icatibant injection
RxNorm normalized name: Icatibant Injection
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Icatibant injection
Trial: 26314822
Drug: Icatibant injection
RxNorm normalized name: Icatibant Injection
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Icatibant injection (2 or 3 injections)
Trial: 26315712
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP) planned in patients with FN risk at or above 20% threshold.
Trial: 26315743
Drug: Ultrasound-facilitated, catheter-directed,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis using 24 mg of tissue-plasminogen activator (t-PA) administered as 1 mg/h for 24 h with a unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters.
Trial: 26315967
Drug: Continuing TKI
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing TKI therapy after RECIST progression
Trial: 26315967
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of TKI therapy after RECIST progression
Trial: 26316385
Drug: 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month
Trial: 26317543
Drug: MTKI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTKI treatment
Trial: 26318254
Drug: Verproside combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verproside combined with IKK inhibitor (BAY11-7082)
Trial: 26318254
Drug: Verproside combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verproside combined with TAK1 inhibitor (5z-7-oxozeaenol)
Trial: 26321472
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of FdCyd and THU
Trial: 26321472
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) administration of FdCyd after THU
Trial: 26321472
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of THU with FdCyd
Trial: 26324363
Drug: JNJ-42756493 10
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 10 mg administered on a 7-days-on/7-days-off schedule
Trial: 26324363
Drug: JNJ-42756493 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 (various doses from 0.5 to 12 mg)
Trial: 26324363
Drug: JNJ-42756493 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 (various doses)
Trial: 26324363
Drug: JNJ-42756493 12
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 12 mg daily
Trial: 26324363
Drug: JNJ-42756493 9
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 9 mg daily
Trial: 26324363
Drug: JNJ-42756493 10
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 10 mg on a 7-days-on/7-days-off schedule
Trial: 26324363
Drug: JNJ-42756493 (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 (starting at 4 mg daily)
Trial: 26325106
Drug: Pimonidazole (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimonidazole (administered intravenously 16-20 hours before surgery)
Trial: 26327481
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose to the thyroid (up to 0.2 Gy)
Trial: 26327481
Drug: High radiation
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High radiation doses (>5 Gy) to pituitary gland
Trial: 26327481
Drug: Nitrosourea chemotherapy
RxNorm normalized name: Bischloroethyl nitrosourea
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrosourea chemotherapy
Trial: 26327481
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose to the thyroid
Trial: 26327694
Drug: Carfilzomib (20S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (20S proteasome inhibitor)
Trial: 26330458
Drug: BQ788 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ788 (3 mg, single intralesional application)
Trial: 26330458
Drug: BQ788 (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ788 (cumulative dosage of 8 mg)
Trial: 26330458
Drug: BQ788 (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ788 (cumulative dosage of 10 mg)
Trial: 26331432
Drug: Bendamustine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 75 mg/m² on days 1 and 2, lenalidomide 25 mg on days 1-21, dexamethasone 40 mg on days 1, 8, 15, and 22
Trial: 26331768
Drug: elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: elosulfase alfa 2.0 mg/kg/week for 52 weeks
Trial: 26332545
Drug: Imetelstat (9.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat (9.4 mg/kg body weight, intravenous infusion every 1 to 3 weeks)
Trial: 26332546
Drug: Imetelstat (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat (7.5 or 9.4 mg/kg intravenously once a week)
Trial: 26333343
Drug: sNGAL ≥179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNGAL ≥179 ng/mL at 6 hours
Trial: 26333343
Drug: sNGAL <179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNGAL <179 ng/mL and sCr <0.3 mg/dL
Trial: 26333343
Drug: sNGAL ≥179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNGAL ≥179 ng/mL
Trial: 26333343
Drug: sCr ≥0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCr ≥0.3 mg/dL
Trial: 26333343
Drug: sNGAL <179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNGAL <179 ng/mL and sCr increase <0.3 mg/dL
Trial: 26333343
Drug: sNGAL ≥179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNGAL ≥179 ng/mL and sCr increase <0.3 mg/dL
Trial: 26333343
Drug: sCr increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCr increase ≥0.3 mg/dL
Trial: 26333343
Drug: Urine NGAL
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours
Trial: 26333941
Drug: Long-term Antiretroviral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term Antiretroviral Therapy (ART)
Trial: 26334219
Drug: VS-6063 (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (425 mg b.i.d.)
Trial: 26334219
Drug: VS-6063 (300-425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (300-425 mg b.i.d.)
Trial: 26334219
Drug: VS-6063 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (various doses)
Trial: 26334219
Drug: VS-6063 (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (500-750 mg b.i.d.)
Trial: 26334878
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with 8.5 g/day of RS type 2 for 4 weeks
Trial: 26335961
Drug: RSV entry
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV entry inhibitor GS-5806
Trial: 26336510
Drug: A-Part Gel(®)
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-Part Gel(®) as an anti-adhesive barrier
Trial: 26336510
Drug: A-Part Gel(®)
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-Part Gel(®)
Trial: 26336609
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (glargine, starting dose 0.1 U/kg/day)
Trial: 26336609
Drug: Oral antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidiabetic drug (OAD) therapy
Trial: 26337145
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg subcutaneous injections at 4-week intervals
Trial: 26337806
Drug: Ixazomib (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib (4.0 mg) plus lenalidomide (25 mg) and dexamethasone (40 mg)
Trial: 26338094
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg every 4 weeks (Q4W)
Trial: 26338094
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg Q3W
Trial: 26338094
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg Q4W
Trial: 26338094
Drug: Patisiran (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran (all doses)
Trial: 26341049
Drug: Albuterol overuse
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol overuse (3 or more canisters per year)
Trial: 26341049
Drug: Albuterol use
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol use on symptom days (80% or more)
Trial: 26341049
Drug: Albuterol use
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol use on symptom-free days (less than 20%)
Trial: 26341049
Drug: Controller medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medication adherence (80% or more of prescribed doses)
Trial: 26341131
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered glucagon at a dose of 2 µg/kg (total mean dose of 1,126 µg over 16 h)